PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer

Thromb Res. 2003;111(4-5):317-9. doi: 10.1016/j.thromres.2003.09.011.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / epidemiology*
  • Breast Neoplasms / genetics*
  • Comorbidity
  • Factor V / genetics*
  • Female
  • Genetic Predisposition to Disease / epidemiology
  • Genetic Predisposition to Disease / genetics
  • Genetic Testing
  • Humans
  • Middle Aged
  • Prevalence
  • Prothrombin / genetics*
  • Tamoxifen / therapeutic use
  • Thromboembolism / epidemiology*
  • Thromboembolism / genetics*
  • Turkey / epidemiology

Substances

  • Antineoplastic Agents
  • Tamoxifen
  • Factor V
  • Prothrombin